Tracon Pharmaceuticals Inc. raised $27 million for its targeted cancer and ophthalmology therapies with a series B round that added New Enterprise Associates (NEA), Biomed Ventures and an undisclosed institutional investor to its global roster of investors, which include Jafco Co. Ltd., Switzerland's Nextech Invest Ltd., Brookline Investments, Arcus Ventures and Japan's BHP – all of whom also participated in the round.